Camber Spine to Roll Out Education Initiatives and Expand Product Portfolio in 2022

Camber Spine, a leading innovator in spine and medical technologies has announced a robust calendar of clinical education and product portfolio expansions in 2022.

Camber Spine notes plans for the year include four spine surgical training labs focused on the Oblique Lateral Interbody Fusion Surgery (OLIF) technique. The labs, part of the Camber Education Program, are designed to give surgeons an opportunity to further their experience accessing the anterior spine (L2-S1) through an oblique approach. The program faculty will use didactic sessions, hands-on cadaveric training and case review to provide a full-day session to benefit surgeon attendees. Additional training labs on will be offered throughout the year on ALIF, LLIF, PLIF and TLIF techniques.

Camber Spine will also be offering unique OLIF training opportunities via its one-on-one Clinical Preceptor Training program with Dr. John I. Williams, Spine Surgeon, ORTHO Northeast, Fort Wayne, IN.

In addition, Camber’s product pipeline is scheduled to produce a number of key product launches throughout 2022, starting with innovative navigation and MIS instruments to be announced later in Q1 and products to compliment a complete posterior approach, also in Q1. Camber will also continue to expand its award-winning Spira and Enza technology platforms in the first three quarters of this year, with a series of product launches, including a full compliment of biologic options.

Camber Spine will be exhibiting and presenting its products (including SPIRA-T, SPIRA-P and ORTHROS) at a number of clinical conferences throughout the year, including AANS/CNS in February, AAOS in March, IMAST and AANS in April, ISASS in June, and other events, including NASS in October, where Camber will be hosting multiple clinical presentations.

“We now offer interbody options for anterior column reconstruction from every possible angle,” said Seth Anderson, Camber’s Chief Innovation Officer. “To support this, education and innovation continue to be our top priorities. Our patented and award-winning technology platforms will be expanding significantly this year, so hosting a broad selection of presentation and training opportunities with thought leaders is timely. This is likely to be our most productive year to date in terms of product launches and hands-on training.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version